Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
“Patients with heFH are difficult to treat in clinical practice. The actual recommended treatment for this category of patients is a statin at the maximum tolerated dose (mainly atorvastatin or rosuvastatin) and if necessary, combination with other lipid-lowering drugs. However, even at this maximum tolerated treatment, their baseline levels of LDL-C in our studies were relatively high (mean around 3.5 and 3.7mmol/l),” he said.
“It is important to emphasize that in both trials, patients were very well treated before the trial,” noted Dr. Farnier. All of them were on statins, with more than 80% on maximum doses, and 55-65% on combination therapy with ezetimibe.”
“Previous studies have shown that only about 20% of heFH patients are able to reach a goal of less than 2.5mmol/l.” noted Dr. Farnier. “Due to the dramatic complementary decrease in LDL-C that our studies obtained with alirocumab, this new strategy is particularly important for this category of patients at high risk of cardiovascular disease.”
© 2017 European Society of Cardiology. All rights reserved